2017 Press Releases

Keyword Search
2017 | 2016 | 2015 | 2014 | 2013
02/13/17Seattle Genetics to Present at Leerink Partners 6th Annual Global Healthcare Conference
BOTHELL, Wash.--(BUSINESS WIRE)--Feb. 13, 2017-- Seattle Genetics, Inc. (NASDAQ:SGEN) announced today that management will present at the Leerink Partners 6th Annual Global Healthcare Conference on Wednesday, February 15 at 2:30pm Eastern Time. The presentation will be webcast live and available for replay from Seattle Genetics’ website at www.seattlegenetics.com in the Investors and News section. About Seattle Genetics ... 
Printer Friendly Version
02/10/17Seattle Genetics Announces Global License Agreement with Immunomedics for Sacituzumab Govitecan (IMMU-132), a Promising Late-Stage ADC for Solid Tumors
-Seattle Genetics to Lead Development, Manufacturing and Commercialization of Sacituzumab Govitecan Globally- -Planned BLA for Triple Negative Breast Cancer Indication; Other Solid Tumors Being Explored in the Clinic- -Conference Call Today at 8:30 a.m. ET- BOTHELL, Wash.--(BUSINESS WIRE)--Feb. 10, 2017-- Seattle Genetics, Inc. (Nasdaq: SGEN), a global biotechnology company, today announced a development and license agre... 
Printer Friendly Version
02/09/17Seattle Genetics Reports Fourth Quarter and Year 2016 Financial Results
-Fourth Quarter 2016 Revenues Were $105.3 Million, Including $70.8 Million in ADCETRIS® (Brentuximab Vedotin) U.S. and Canada Net Sales- -ADCETRIS Supplemental Biologics License Application for Cutaneous T-Cell Lymphoma Planned in Mid-2017- -Top-Line Data from ADCETRIS Phase 3 ECHELON-1 Trial Expected in 2017 and from Phase 3 ECHELON-2 Trial in 2018- -Regulatory Discussions Planned to Advance Enfortumab Vedotin (ASG-... 
Printer Friendly Version
01/19/17Seattle Genetics to Host Conference Call and Webcast Discussion of Fourth Quarter and Year 2016 Financial Results on February 9, 2017
BOTHELL, Wash.--(BUSINESS WIRE)--Jan. 19, 2017-- Seattle Genetics, Inc. (Nasdaq: SGEN) announced today that it will report its fourth quarter and year 2016 financial results on Thursday, February 9, after the close of financial markets. Following the results announcement, company management will host a conference call and webcast discussion of the results and provide a general corporate update. Access to the event can be obtained as follows: ... 
Printer Friendly Version
01/05/17Seattle Genetics Initiates Phase 1 Trial of SGN-CD352A for Patients with Relapsed or Refractory Multiple Myeloma
-SGN-CD352A, a Novel Antibody-Drug Conjugate (ADC), Represents Seattle Genetics’ 9th Clinical Stage Program in a Robust Pipeline of Empowered Antibody Therapies- -Preclinical Data Showing Potent Antitumor Activity of SGN-CD352A in B-cell Cancers Presented at the 2016 American Association of Cancer Research Annual Meeting- BOTHELL, Wash.--(BUSINESS WIRE)--Jan. 5, 2017-- Seattle Genetics, Inc. (NASDAQ: SGEN), a global biotechnolog... 
Printer Friendly Version